A study to evaluate ABT-450 with Ritonavir (ABT-450/r) and ABT-267 in Japanese adults with chronic Hepatitis C Virus infectio
- Conditions
- Chronic Hepatitis C Virus infection
- Registration Number
- JPRN-jRCT2080221883
- Lead Sponsor
- AbbVie GK
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 96
Male or female between the age 18 and 75 years, inclusive.
-Previously received Pegylated interferon alpha-2a/Ribavirin.
-Chronic hepatitis C virus infection.
-Plasma hepatitis C virus ribonucleic acid level greater than 10,000 International Units/milliliter.
-Voluntarily sign an informed consent.
-Histry of severe, life-threatening sensitivity to any drug.
-Females who are pregnant or plan to become pregnant, or breastfeeding.
-Recent histry of drug or alcohol abuse.
-Positive test result for hepatitis B surface antigen or anti-Human immunodeficiency virus antibodies.
-Any current or past clinical evidence of cirrhosis.
-Previous use of any investigational or commerciallyavailable anti-Hepatitis C virus agent other than Pegylated interferon alpha-2a and Ribavirin, including previous exposure to ABT-450 or ABT-267.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method